Materials and methods for improved phosphotransferases
AssigneeJanssen Biotech, Inc.
InventorWilliam Lloyd Perry, III
Life of this patent
Estimating the term…
Loading patent…
AssigneeJanssen Biotech, Inc.
InventorWilliam Lloyd Perry, III
Estimating the term…
Described herein are non-naturally occurring neomycin phosphotransferase (NPT) proteins and nucleic acid sequences encoding such NPT proteins. In a specific embodiment, the non-naturally occurring NPT proteins have reduced activity relative to wild-type NPT. The non-naturally occurring NPT proteins provided herein are useful as a selectable marker for screening transformed or transfected cells. Also provided herein are vectors and kits comprising a nucleic acid sequence encoding a non-naturally occurring NPT protein, and methods of producing cells expressing the non-naturally occurring NPT protein and a protein of interest or a non-coding RNA sequence of interest.
A non-naturally occurring neomycin phosphotransferase (NPT) with neomycin phosphotransferase activity, wherein the non-naturally occurring NPT comprises an amino acid sequence of a wild-type neomycin phosphotransferase with:
A non-naturally occurring neomycin phosphotransferase (NPT) with neomycin phosphotransferase activity, wherein the non-naturally occurring NPT comprises the amino acid sequence of SEQ ID NO:1 with:
A selectable marker means for conferring resistance to kanamycin when introduced into a bacterial cell, and to G418 when introduced into a mammalian cell;
A method for manufacturing a producer cell line comprising:
A method for selecting a cell with stable chromosomal integration of an exogenous nucleic acid sequence comprising:
A method for selecting a mammalian cell with a stable episome comprising:
A method for selecting a mammalian cell transiently expressing a transgene comprising:
Dependencies are inferred from the claim text.